A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
← catalyst calendarNCT07587710 · readout in 469 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
35estimated
Sites
2
Country
Slovakia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-13 | estimated | When the study began enrolling |
| Primary completion | 2027-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Intervention
- Drug: NNC0487-0111
Primary outcome
what the primary-completion date above is the date OFAUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
measured From pre-dose on Day 1 up to Day 28
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed